| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
tCFA15 modulates lipid metabolism enzymes and membrane properties, thereby influencing energy metabolism and inflammation-related signaling pathways. It can promote the differentiation of nerve cells and may regulate the Notch signaling pathway. tCFA15 stimulates arginine vasopressin secretion in nerve terminals of the neurohypophysis. Its mechanism of action involves interaction with specific molecular targets and pathways. The compound's neurobiological activity makes it a valuable research tool.
|
|---|---|
| ln Vitro |
tCFA15 (10 nM-1 μM) stimulates neuronal development at the expense of astrocytes via Notch1, which has a dose-dependent effect on the differentiation of neural stem cell-derived neurospheres. Notch1 mRNA levels in spheroids are selectively decreased by tCFA15 (1 μM), and this effect is similarly seen in lower Notch1 expression in cultures of neurons and glia [1]. Neurohypophyseal nerve terminals secrete arginine vasopressin when tCFA15 is present [2].
In vitro, tCFA15 stimulates arginine vasopressin secretion in nerve terminals of the neurohypophysis. It promotes the differentiation of nerve cells and may regulate the Notch signaling pathway. As a trimethyl cyclohexenonic long-chain fatty alcohol, tCFA15 modulates lipid metabolism enzymes and membrane properties, influencing energy metabolism and inflammation-related signaling pathways. These activities make it a valuable tool for studying neurobiology and lipid metabolism. |
| ln Vivo |
In vivo studies of tCFA15 are limited, as it is primarily used as a research tool in neurobiological and metabolic studies. The compound's ability to promote nerve cell differentiation and regulate Notch signaling suggests potential applications in neurodevelopmental and neurodegenerative research. Its modulation of lipid metabolism and inflammation-related pathways may also have implications for metabolic disorders. Further in vivo studies are needed to fully characterize its efficacy and safety profile.
|
| Enzyme Assay |
For in vitro enzyme/receptor binding assays, tCFA15 can be evaluated using assays that measure its effects on lipid metabolism enzymes and membrane properties. The compound is incubated with relevant enzymes or membrane preparations at various concentrations. Enzyme activity is quantified using standard biochemical methods. The compound's effects on membrane fluidity and properties can be assessed using biophysical techniques such as fluorescence anisotropy. Its interaction with Notch signaling components can be evaluated using reporter assays or protein interaction studies.
|
| Cell Assay |
For in vitro cellular experiments, tCFA15 is tested in neuronal cell lines or primary neurons to evaluate its effects on differentiation and signaling. Cells are cultured in appropriate media and treated with various concentrations of the compound. Neuronal differentiation is assessed by measuring neurite outgrowth and expression of neuronal markers. Notch signaling activity is evaluated using reporter assays or by measuring the expression of Notch target genes. The compound's effects on cell viability, proliferation, and metabolism are monitored using standard assays.
|
| Animal Protocol |
For in vivo animal experiments, tCFA15 can be administered to rodents via various routes including oral gavage, intravenous injection, or intraperitoneal injection, depending on its solubility and pharmacokinetic properties. The compound's effects on neurodevelopment, neuroprotection, or metabolic regulation can be evaluated in appropriate animal models. Typical doses may range from 1 to 50 mg/kg. Behavioral tests, histological analysis, and biochemical markers are assessed. Animal studies should follow appropriate ethical guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of tCFA15 are not extensively characterized in the literature. As a long-chain fatty alcohol with a molecular weight of 364.61, it is expected to have moderate lipophilicity and tissue distribution. When administered systemically, the compound would likely be metabolized by liver enzymes and distributed to various tissues. Its half-life in circulation would depend on its stability and clearance mechanisms. Further pharmacokinetic studies would be needed to fully characterize its absorption, distribution, metabolism, and excretion profile in vivo.
|
| Toxicity/Toxicokinetics |
Toxicological data for tCFA15 are limited, as it is primarily a research tool. As a fatty acid analog, it is generally considered to have low toxicity at concentrations typically used for research. Standard toxicological assessments would include cytotoxicity screening in relevant cell lines and preliminary in vivo toxicity in rodent models. As with all research chemicals, appropriate safety precautions should be taken when handling tCFA15, including the use of personal protective equipment and adherence to institutional safety guidelines.
|
| References |
|
| Additional Infomation |
2-Cyclohexen-1-one, 3-(15-hydroxypentadecanyl)-2,4,4-trimethyl- is a long-chain fatty alcohol.
tCFA15 is a research compound used to study neurobiology, lipid metabolism, and Notch signaling. No clinical trials or regulatory approvals have been reported for this compound as a therapeutic agent. It is available from various chemical suppliers for research purposes only. The compound is a trimethyl cyclohexenonic long-chain fatty alcohol with a 15-carbon side chain that promotes nerve cell differentiation and stimulates arginine vasopressin secretion. |
| Molecular Formula |
C24H44O2
|
|---|---|
| Molecular Weight |
364.60496
|
| Exact Mass |
364.334
|
| CAS # |
220757-88-0
|
| PubChem CID |
9799188
|
| Appearance |
Light yellow to yellow ointment
|
| LogP |
7.145
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
26
|
| Complexity |
420
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C(C)=C(CCCCCCCCCCCCCCCO)C(C)(C)CC1
|
| InChi Key |
FGMAOXGOTRUOKJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H44O2/c1-21-22(24(2,3)19-18-23(21)26)17-15-13-11-9-7-5-4-6-8-10-12-14-16-20-25/h25H,4-20H2,1-3H3
|
| Chemical Name |
3-(15-hydroxypentadecyl)-2,4,4-trimethylcyclohex-2-en-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~130 mg/mL (~356.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (5.95 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7427 mL | 13.7137 mL | 27.4273 mL | |
| 5 mM | 0.5485 mL | 2.7427 mL | 5.4855 mL | |
| 10 mM | 0.2743 mL | 1.3714 mL | 2.7427 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
